Welcome to our dedicated page for Quoin Pharmaceuticals SEC filings (Ticker: QNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quoin Pharmaceuticals Ltd. (QNRX) filings document a State of Israel registrant whose Nasdaq-listed American Depositary Shares each represent 35 ordinary shares. Recent 8-K reports record quarterly and annual financial results, Regulation FD disclosures and material events tied to the company's rare-disease drug-development programs.
The filing record includes disclosures about QRX003 regulatory designations for Netherton Syndrome, QRX009 topical rapamycin delivery technologies, capital-structure matters and board compensation arrangements. These reports also identify the ADS and ordinary-share structure and exchange listing for QNRX securities.
Quoin Pharmaceuticals (NASDAQ:QNRX), a late clinical-stage specialty pharmaceutical company, announced that the FDA has granted Rare Pediatric Disease (RPD) Designation for their lead asset QRX003, targeting Netherton Syndrome. This significant regulatory milestone was disclosed in an 8-K filing dated June 24, 2025.
The RPD designation for QRX003 represents an important development in the company's rare and orphan disease pipeline, potentially accelerating the path to market for their Netherton Syndrome treatment.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) filed a Form 8-K to announce that its Board has scheduled the 2025 Annual General Meeting of Shareholders ("2025 AGM") for August 21, 2025. Because this date is more than 30 days earlier than the anniversary of the 2024 AGM, previously disclosed shareholder-proposal deadlines are no longer valid.
Revised submission windows:
- Rule 14a-8 proposals: must be received by June 30, 2025 for inclusion in the Company’s proxy materials.
- Universal proxy (Rule 14a-19) director nominations: notice must also be delivered by June 30, 2025, the 10th calendar day after this report’s public announcement.
No financial results, transactions, or strategic changes were disclosed. The filing is primarily a procedural notice affecting shareholders who intend to submit proposals or nominate directors.